Search - tctmd.com

Displaying 1 - 20 of 146

Sort: Relevancy | Date

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Daily News

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

Yael L. Maxwell

December 15, 2025

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

Todd Neale

November 08, 2025

News Daily News

Evolocumab Wins for Primary Prevention in VESALIUS-CV

L.A. McKeown

October 03, 2025

News Conference News ESC 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Michael O'Riordan

September 10, 2025

News Conference News ESC 2025

WHF Stresses the Importance of Polypills in Global Fight Against CVD

Yael L. Maxwell

September 09, 2025

News Conference News ESC 2025

Olezarsen Brings Moderately High Triglycerides Under Control: ESSENCE-TIMI 73b

Caitlin E. Cox

August 31, 2025

News Daily News

Evolocumab Gains Expanded Indication for Primary Prevention

Michael O'Riordan

August 26, 2025

News Daily News

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Michael O'Riordan

August 06, 2025

News Daily News

Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050

Todd Neale

July 16, 2025

News Daily News

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Michael O'Riordan

May 07, 2025

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

News Daily News

Tirzepatide Bests Semaglutide for Weight Loss: SURMOUNT-5 Top-line Results

Michael O'Riordan

December 04, 2024

News Conference News ESC 2024

Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events

Caitlin E. Cox

August 31, 2024

News Daily News

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Michael O'Riordan

April 17, 2024

News Conference News ACC 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Michael O'Riordan

April 12, 2024

News Conference News ACC 2024

Need a Statin for Primary Prevention? There’s an App for That

Michael O'Riordan

April 10, 2024

News Daily News

Bempedoic Acid Gains CV Risk Reduction Indication

Todd Neale

March 22, 2024

Advertisement

Year in Review: Top Prevention Stories of 2025

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

Evolocumab Wins for Primary Prevention in VESALIUS-CV

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

WHF Stresses the Importance of Polypills in Global Fight Against CVD

Olezarsen Brings Moderately High Triglycerides Under Control: ESSENCE-TIMI 73b

Evolocumab Gains Expanded Indication for Primary Prevention

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Tirzepatide Bests Semaglutide for Weight Loss: SURMOUNT-5 Top-line Results

Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Need a Statin for Primary Prevention? There’s an App for That

Bempedoic Acid Gains CV Risk Reduction Indication

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content